Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by MrMugsyon Jan 10, 2022 9:21am
103 Views
Post# 34299317

RE:RE:Pipeline: Pre-Launch Drugs at Knight

RE:RE:Pipeline: Pre-Launch Drugs at Knight
gudisgood wrote:
MrMugsy,

Not sure if you saw my previous post about this.

Perhaps I have this wrong, but if you look at the latest Annual Information Form (page 30), they define Launched and Marketed the following way:

Launched: product has been on the market under 5 years
Marketed: product has been on the market over 5 years

Source: https://www.gud-knight.com/wp-content/uploads/AIF-2020_VF.pdf



Interesting Gudisgood and I see the order at the bottom of the product spreadsheet showing 
Launched before marketed - to your point, that would make sense.

This is a little confusing as we're not making money from EXELON sales yet as we wait for tranfers to be completed.  From this I assumed the drug would go to "launched" after we are selling.  Likely not the case based on what you are saying.

Getting confused.
<< Previous
Bullboard Posts
Next >>